ABSTRACT OBJECTIVES This study sought to evaluate the use of the Direct Flow Medical (DFM) transcatheter heart valve (Direct Flow Medical, Santa Rosa, California) for the treatment of noncalcific pure aortic regurgitation (AR).
A lthough transcatheter aortic valve replacement (TAVR) has become the standard of care for extreme-and high-risk patients with symptomatic aortic stenosis, pure AR is still generally considered a relative contraindication for TAVR (1) (2) (3) (4) (5) . This is predominantly due to the fact that most pure AR patients can undergo surgical aortic valve replacement even in high operative risk situations; TAVR is still considered off-label for almost all transcatheter valves. This is due to the fact that TAVR valves were designed to anchor on the native annulus in the presence of valvular calcifi- 
DFM Aortic Valve Implantation in Pure Aortic Regurgitation leaflet aortic heart valve, a delivery system, and exchange system that can be implanted either via a transfemoral, subclavian, or direct aortic approach and has been described elsewhere in detail (13, 14) . In Schofer et al. Multislice computed tomography of a patient with severe pure AR with a noncalcified aortic valve (top) and a patient with a very mild calcified aortic valve (bottom). Schofer et al.
The 30-day all-cause mortality was 9% caused by a noncardiac death due to pneumonia and acute res- Schofer et al. 
